Undifferentiated Connective-Tissue Disease

Back

Background

Connective-tissue diseases (CTDs) manifest with a wide range of clinical findings and laboratory abnormalities. The diversity of signs and symptoms frequently complicates the diagnosis of a rheumatic disease.

Diagnostic and classification criteria have been established for many CTDs, including the following:

Some of these disease criteria overlap, further complicating the diagnostic workup in patients with a potential CTD. Unclassifiable symptoms, physical examination findings, or serological results suggestive of a CTD frequently lead to diagnoses such as incomplete lupus, latent lupus, overlap syndrome, and undifferentiated connective-tissue disease (UCTD). Conceptually, these terms may seem synonymous; however, specific definitions are necessary for appropriate diagnostic, therapeutic, and prognostic determinations.

In 1980, LeRoy et al proposed the concept of undifferentiated connective-tissue syndromes (UCTS) to characterize mixed or overlapping syndromes.[9] Since that time, innumerable case reports, case series, and clinical studies have used variable criteria to define UCTD. Such variation in the definition of UCTD results in ambiguity of study results and difficulty with interpreting the findings and conclusions.

In 1999, Mosca et al proposed preliminary classification criteria for UCTD that have become increasingly accepted and used.[10] The authors suggested defining cases of UCTD as those in which signs and symptoms are consistent with a CTD but that do not fulfill the classification or diagnostic criteria for any one of the defined CTDs (ie, RA, SLE, SSc, PM/DM, MCTD, SS). In order to fulfill the criteria for UCTD, antinuclear antibodies must be present, along with a disease duration of at least 3 years. Cases with a shorter duration should be described as early UCTD.

Other definitions for UCTD have been proposed.[9, 11, 12, 13, 14, 15, 16, 17] However, many of these definitions are limited by the fact that they may lead to the inclusion of a defined CTD manifesting early or in an incomplete form.

In 2008, Mosca et al admitted that while their proposed classification criteria exclude most patients with an evolving definite CTD, limitations are evident. Their criteria do not allow the diagnosis of UCTD to be made at onset. In addition, the criteria do not exclude a slowly evolving or an incomplete definite CTD.[18] To avoid the misdiagnosis of transitory or early defined CTD, exclusion criteria were appended to the proposed classification criteria above.[19] These preliminary classification criteria for UCTD are listed in Table 1, although no mutual agreement has been reached regarding the criteria for diagnosis of UCTD.[20]

Table 1. Preliminary Classification Criteria for Undifferentiated Connective-Tissue Disease



View Table

See Table

Pathophysiology

As with all the CTDs, the etiology of UCTD is unknown, and the lack of validated classification criteria has complicated the task of elucidating the pathophysiology. Generally, autoimmune diseases, including UCTD, are believed to exist in different phases.[21, 22]

The initial phase may occur many years prior to diagnosis, during which time the patient may be asymptomatic and may lack serum autoantibodies. Currently, patients with autoimmune disease are believed to have a genetic predisposition. In the second phase, autoantibodies may appear in the serum despite an absence or paucity of symptoms. The interval between autoantibody appearance and significant symptom onset is highly variable among individual patients and the specific autoantibodies. Finally, signs and symptoms of the autoimmune disease appear, leading to a definitive diagnosis. Environmental factors likely trigger the onset of this final stage. A clinical diagnosis of early UCTD[10] may be made in the second phase, and some of these cases may evolve into a definite CTD or may remain undifferentiated.

UCTD has been associated with numerous autoantibodies, but whether these autoantibodies are etiopathogenic or simply markers of the disease is unknown. Specific autoantibodies to HSP60, HSP65, and transcription factor Sp1 were identified in patients with UCTD and proposed to be pathogenic; however, further research is necessary to clarify this issue.[23, 24]

Research is being directed to evaluate disease features that may delineate the evolution of UCTD. In 2008, Szodoray et al assessed whether abnormalities in the distribution of various immune-competent T-cell populations exist in patients with UCTD and whether certain immune phenotypes predict subsequent development of defined CTDs.[25] The relative and absolute number of natural regulatory T cells (Tregs) decreased in patients with UCTD when compared with controls.

In the patients who developed a definite CTD, the number of natural Tregs was further decreased, suggesting that patients with lower numbers of Treg cell subsets may be more likely to develop a definite CTD. In a similar study, the levels of Treg cells were significantly lower in patients with systemic sclerosis compared with patients with UCTD or healthy controls; in patients with limited cutaneous systemic sclerosis, Treg cells were inversely correlated to disease duration, suggesting that their levels may represent a marker of disease progression.[49]

Furthermore, it has been proposed that vitamin D deficiency may contribute to pathological changes in the number and function of CD4+ T-helper cell subsets in patients with UCTD, and vitamin D supplementation may improve the fine balance of proinflammatory and anti-inflammatory processes in the disease.[26]

Epidemiology

Frequency

International

No epidemiologic studies have been completed for UCTD, and disease prevalence can be estimated only by extrapolating data from small case series. Mosca et al (1999) note that 20%-52% of patients in rheumatology clinics with a CTD may have UCTD.[10] This wide range is attributable to varying selection criteria. Disease duration of less than one year may result in transient disease or early-defined CTD being classified as UCTD.

Guerrero et al conducted a similar study of 94 patients over 12 months in Colombia. They concluded that arthritis, Raynaud phenomenon, and the presence of photosensitivity were predictors for the development of CTD. A consensus is required to establish criteria for the classification of UCTD.[27]

Mortality/Morbidity

UCTD may evolve into a defined CTD in 20%-40% of patients, and 50%-60% remain undifferentiated.[18] Ten to 20% percent of patients have symptoms that eventually subside and never evolve into a defined CTD.[25] The likelihood of evolution to a defined CTD is highest during the first 3-5 years of the disease,[28] and the rate of evolution continues to decrease thereafter.[29] Patients who develop a defined CTD late have been noted to have milder disease with a lower incidence of serious adverse events and a good prognosis.[15, 29]

In contrast to the defined CTDs, UCTD is characterized by a mild clinical picture. However, exceptions are notable, as UCTD has been associated with severe, organ-involving, and life-threatening complications, including thrombotic thrombocytopenic purpura,[30] myocarditis,[31] nonspecific interstitial pneumonia,[32] cardiovascular disease,[33] vasculitis,[34] cardiac tamponade,[35] and hepatic injury.[36] Survival rates associated with UCTD are similar to those associated with RA and SLE.[37]

Race-, Sex-, and Age-related Demographics

One study in the United States reported 72% of patients with UCTD were white.[38] Two Italian studies[11, 29] and a Hungarian study[15] did not report the racial characteristics of UCTD cases. Racial prevalence is still uncertain given the limited available data and possible selection bias introduced in those studies.

As with many other autoimmune CTDs, UCTD is much more likely to be diagnosed in females. Reported percentages of UCTD diagnoses in females are 78% in the United States,[38] 93%-95% in Italy,[11, 29] and 94% in Hungary.[15]

UCTD is typically diagnosed in patients in the 3rd to 5th decade of life. However, pediatric and elderly-onset cases have been reported.[38] Patients with SLE who have a prior history of UCTD are diagnosed with SLE approximately 6 years later than patients with SLE who do not have a prior history of UCTD.[15]

History

Patients with undifferentiated connective-tissue disease (UCTD) may present with various signs and symptoms. The most common manifestations at presentation include the following[11, 15, 29, 38, 39] :

The proposed classification criteria for UCTD[10] include any sign or symptom that may be included in the classification criteria of systemic lupus erythematosus (SLE), mixed CTD (MCTD), systemic sclerosis (SSc), polymyositis/dermatomyositis (PM/DM), rheumatoid arthritis (RA), and Sjögren syndrome (SS). The following incomplete list of symptoms may be noted in patients with UCTD and are included as criteria for the classification of UCTD:

Physical

Physical findings of UCTD may be localized or diffuse. The potential physical manifestations of UCTD are best described by organ systems, as follows:

Laboratory Studies

Laboratory test screening is helpful to identify markers that may suggest autoimmune inflammatory disease. Routine screening tests for undifferentiated connective-tissue disease (UCTD) should include the following:

Other studies to consider on a case-by-case basis include the following:

Anti-U1-RNP and Anti-Ro/SSA antibodies represent the antinuclear specificities most frequently detected in UCTD. Anti-Ro/SSA immunoglobulin G (IgG) antibodies are very common in UCTD.[45] A 2008 study by Zold et al suggested that vitamin D deficiency in patients with UCTD may play a role in progression to a defined CTD.[46]

Imaging Studies

Chest radiography in patients with UCTD may be normal or may show signs of pleural effusion, pericardial effusion, enlarged cardiac silhouette, longstanding pulmonary hypertension, or interstitial lung disease. Features of interstitial pneumonia may overlap with diagnostic criteria for interstitial pneumonia with autoimmune features.[32]  Computed tomography (CT) of the chest, particularly high-resolution CT scanning, may better characterize pulmonary disease associated with CTD.

Salivary gland ultrasonography (SGUS) was found to have good sensitivity and high specificity in differentiating Sjögren syndrome (SS) from UCTD. In a study that included 55 patients with SS and 54 with UCTD, patients with SS showed a higher SGUS score than those with UCTD [mean 2.2  vs 0.2, P < 0.0001). An SGUS cut-off >2 showed a sensitivity of 65%, a specificity of 96%, a positive predictive value of 95%, and a negative predictive value of 73% for SS diagnosis.[53]

Other Tests

See the list below:

Approach Considerations

A patient with undifferentiated connective-tissue disease (UCTD) can be evaluated and treated primarily as an outpatient. Nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials (eg, hydroxychloroquine), and corticosteroids are the mainstay of therapy. Immunosuppressive drugs are generally reserved for treating specific clinical manifestations and when there is major organ involvement.

Surgery for patients with UCTD is not routinely necessary and should be initiated only when indicated for diagnosis or treatment.

 

Consultations

See the list below:

Activity

See the list below:

Medication Summary

Nonsteroidal anti-inflammatory drugs (NSAIDs), antimalarials (eg, hydroxychloroquine), and corticosteroids are the mainstay of therapy in patients with undifferentiated connective-tissue disease (UCTD). Immunosuppressive drugs are generally reserved for treating specific clinical manifestations and when there is major organ involvement.

Mosca et al (2008) found that 93% of patients with UCTD were initially treated with corticosteroids and/or antimalarials, and 2% were started on immunosuppressive medications. After 10 years of follow-up, 16% of patients were no longer receiving therapy, 36% were being treated with hydroxychloroquine plus corticosteroids, 10% were taking corticosteroids alone, and no patients were receiving cytotoxic immunosuppressive therapy.[18]

Bodolay et al (2003) prescribed low-dose corticosteroids only when NSAIDs were deemed ineffective.[15] Common indications for systemic corticosteroids included recurrent serositis, skin vasculitis, and synovitis. Antimalarials were administered for photosensitivity and severe rash. The authors concluded that aggressive immunosuppressive therapy for "true" UCTD is neither necessary nor justified.

Naproxen (Naprosyn)

Clinical Context:  For relief of mild-to-moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of cyclooxygenase, which is responsible for prostaglandin synthesis.

Class Summary

NSAIDs may be beneficial for analgesic, antipyretic, anti-inflammatory, or antiplatelet effects. These medications inhibit the enzyme cyclooxygenase, resulting in a generalized decrease in prostaglandin production, ultimately reducing pain and inflammation. Other mechanisms may also exist, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions.

Arthritis and arthralgias may respond to NSAIDs alone or in combination with an antimalarial (see below).

Celecoxib (Celebrex)

Clinical Context:  Selectively inhibits cyclooxygenase-2 and reduces prostaglandin synthesis

Class Summary

The inducible cyclooxygenase-2 (COX-2) isoenzyme is produced during inflammatory conditions, resulting in increased production of proinflammatory prostaglandins that cause pain and swelling. COX-2 inhibitors selectively block the COX-2 isoenzyme and may minimize adverse effects associated with traditional NSAIDs (eg, gastrointestinal bleeding).

Hydroxychloroquine (Plaquenil)

Clinical Context:  Inhibits chemotaxis of eosinophils and locomotion of neutrophils and impairs complement-dependent antigen-antibody reactions. Hydroxychloroquine sulfate 200 mg is equivalent to 155 mg hydroxychloroquine base and 250 mg chloroquine phosphate.

Class Summary

These agents may inhibit the chemotactic properties of pro-inflammatory leukocytes (eg, polymorphonuclear cells, lymphocytes). They may also interfere with intracellular processing of autoantigenic peptides.

Antimalarials may be used with or without NSAIDs to control arthralgias/arthritis, constitutional symptoms, and mucocutaneous manifestations.

Prednisone (Deltasone, Orasone, Meticorten)

Clinical Context:  Immunosuppressant for treatment of autoimmune disorders. May decrease inflammation by reversing increased capillary permeability and suppressing PMN activity.

Class Summary

Corticosteroids inhibit the cascade of inflammatory and immune mechanisms at the cellular level, resulting in profound anti-inflammation and modification of the immune response. The pharmacologic effects and adverse effects of corticosteroids are influenced by the drug preparation, dose, dosing schedule, and route of administration. They vary with the individual patient and disease process.

These drugs are commonly used in combination with other medications to control the signs and symptoms of inflammation.

Methotrexate (Rheumatrex, Folex PFS)

Clinical Context:  Unknown mechanism of action. Analog of folic acid and inhibits dihydrofolate reductase and, ultimately, DNA synthesis. Methotrexate also inhibits the enzyme 5-aminoimidazole-4-carboxamidoribonucleotide (AICAR) transformylase, leading to intracellular accumulation of AICAR and extracellular adenosine release. The adenosine has anti-inflammatory properties.

Methotrexate is very effective in the treatment of inflammatory arthritis and other systemic manifestations of UCTD. Ameliorates symptoms of inflammation (eg, pain, swelling, stiffness).

Available as 2.5-mg tab or 25-mg/mL vial.

Azathioprine (Imuran)

Clinical Context:  A purine analog that interferes with the synthesis of adenosine and guanine resulting in inhibited synthesis of DNA, RNA, and proteins. May decrease proliferation of immune cells and may be effective for treatment of articular and extra-articular manifestations of connective-tissue disease.

Class Summary

These agents suppress key factors of the immune system and are typically reserved for severe manifestations of UCTD.

Nifedipine (Procardia, Procardia XL, Adalat CC)

Clinical Context:  During depolarization, inhibits calcium ions from entering the slow channels and voltage-sensitive areas of vascular smooth muscle.

Diltiazem (Cardizem, Cardizem SR)

Clinical Context:  During depolarization, inhibits calcium ions from entering the slow channels and voltage-sensitive areas of vascular smooth muscle.

Class Summary

These agents relax vascular smooth muscle and decrease peripheral vascular resistance. They may help control the signs and symptoms of Raynaud phenomenon.

Further Outpatient Care

Patients with undifferentiated connective-tissue disease (UCTD) are typically monitored for progression of specific manifestations, evolution to a defined CTD, and safety and efficacy of treatment. The frequency of outpatient visits necessary depends on the severity of disease. During the first 5 years postdiagnosis, the frequency of follow-up visits may be greater, given the propensity for UCTD to evolve early in the disease course.

Prognosis

Prognostic considerations include the following:

Patient Education

Patients with UCTD, as well as their immediate family members, should be educated about the prognosis of UCTD and the potential for the disease to evolve into a defined CTD (eg, SLE, systemic sclerosis, mixed CTD). Furthermore, education should focus on the following:

Author

Bernard Hildebrand, MD, MA, Associate Program Director, San Antonio Military Medical Center Rheumatology Fellowship

Disclosure: Nothing to disclose.

Coauthor(s)

Daniel F Battafarano, DO, MACP, FACR, Program Director, Rheumatology Fellowship, San Antonio Uniformed Services Health Education Consortium, San Antonio Military Medical Center; Professor of Medicine, Uniformed Services University of the Health Sciences, F Edward Hebert School of Medicine; Adjunct Professor of Medicine, University of Texas Health San Antonio

Disclosure: Nothing to disclose.

Specialty Editors

Francisco Talavera, PharmD, PhD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Elliot Goldberg, MD, Dean of the Western Pennsylvania Clinical Campus, Professor, Department of Medicine, Lewis Katz School of Medicine at Temple University

Disclosure: Nothing to disclose.

Chief Editor

Herbert S Diamond, MD, Visiting Professor of Medicine, Division of Rheumatology, State University of New York Downstate Medical Center; Chairman Emeritus, Department of Internal Medicine, Western Pennsylvania Hospital

Disclosure: Nothing to disclose.

References

  1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988 Mar. 31(3):315-24. [View Abstract]
  2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov. 25(11):1271-7. [View Abstract]
  3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 Sep. 40(9):1725. [View Abstract]
  4. American Rheumatism Association. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980 May. 23(5):581-90. [View Abstract]
  5. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975 Feb 13. 292(7):344-7. [View Abstract]
  6. Alarcón-Segovia D, Cardiel MH. Comparison between 3 diagnostic criteria for mixed connective tissue disease. Study of 593 patients. J Rheumatol. 1989 Mar. 16(3):328-34. [View Abstract]
  7. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM. Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 1993 Mar. 36(3):340-7. [View Abstract]
  8. Fox RI, Saito I. Criteria for diagnosis of Sjogren's syndrome. Rheum Dis Clin North Am. 1994 May. 20(2):391-407. [View Abstract]
  9. LeRoy EC, Maricq HR, Kahaleh MB. Undifferentiated connective tissue syndromes. Arthritis Rheum. 1980 Mar. 23(3):341-3. [View Abstract]
  10. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol. 1999 Sep-Oct. 17(5):615-20. [View Abstract]
  11. Danieli MG, Fraticelli P, Franceschini F, et al. Five-year follow-up of 165 Italian patients with undifferentiated connective tissue diseases. Clin Exp Rheumatol. 1999 Sep-Oct. 17(5):585-91. [View Abstract]
  12. Greer JM, Panush RS. Incomplete lupus erythematosus. Arch Intern Med. 1989 Nov. 149(11):2473-6. [View Abstract]
  13. Ganczarczyk L, Urowitz MB, Gladman DD. "Latent lupus". J Rheumatol. 1989 Apr. 16(4):475-8. [View Abstract]
  14. Swaak AJ, van de Brink H, Smeenk RJ, Manger K, Kalden JR, Tosi S. Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford). 2001 Jan. 40(1):89-94. [View Abstract]
  15. Bodolay E, Csiki Z, Szekanecz Z, et al. Five-year follow-up of 665 Hungarian patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2003 May-Jun. 21(3):313-20. [View Abstract]
  16. Cavazzana I, Franceschini F, Belfiore N, et al. Undifferentiated connective tissue disease with antibodies to Ro/SSa: clinical features and follow-up of 148 patients. Clin Exp Rheumatol. 2001 Jul-Aug. 19(4):403-9. [View Abstract]
  17. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009 Aug. 28(8):915-21. [View Abstract]
  18. Mosca M, Tani C, Bombardieri S. A case of undifferentiated connective tissue disease: is it a distinct clinical entity?. Nat Clin Pract Rheumatol. 2008 Jun. 4(6):328-32. [View Abstract]
  19. Doria A, Mosca M, Gambari PF, Bombardieri S. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both?. J Rheumatol. 2005 Feb. 32(2):213-5. [View Abstract]
  20. Conti V, Esposito A, Cagliuso M, Fantauzzi A, Pastori D, Mezzaroma I. Undifferentiated connective tissue disease - an unsolved problem:revision of literature and case studies. Int J Immunopathol Pharmacol. 2010 Jan-Mar. 23(1):271-8. [View Abstract]
  21. Bizzaro N, Tozzoli R, Shoenfeld Y. Are we at a stage to predict autoimmune rheumatic diseases?. Arthritis Rheum. 2007 Jun. 56(6):1736-44. [View Abstract]
  22. Cappelli S, Bellando Randone S, Martinovic D, Tamas MM, Pasalic K, Allanore Y, et al. "To Be or Not To Be," Ten Years After: Evidence for Mixed Connective Tissue Disease as a Distinct Entity. Semin Arthritis Rheum. 2011 Sep 27. [View Abstract]
  23. Horvath L, Czirjak L, Fekete B, et al. Levels of antibodies against C1q and 60 kDa family of heat shock proteins in the sera of patients with various autoimmune diseases. Immunol Lett. 2001 Jan 1. 75(2):103-9. [View Abstract]
  24. Spain TA, Sun R, Gradzka M, et al. The transcriptional activator Sp1, a novel autoantigen. Arthritis Rheum. 1997 Jun. 40(6):1085-95. [View Abstract]
  25. Szodoray P, Nakken B, Barath S, Gaal J, Aleksza M, Zeher M. Progressive divergent shifts in natural and induced T-regulatory cells signify the transition from undifferentiated to definitive connective tissue disease. Int Immunol. 2008 Aug. 20(8):971-9. [View Abstract]
  26. Zold E, Szodoray P, Nakken B, Barath S, Kappelmayer J, Csathy L, et al. Alfacalcidol treatment restores derailed immune-regulation in patients with undifferentiated connective tissue disease. Autoimmun Rev. 2011 Jan. 10(3):155-62. [View Abstract]
  27. Guerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int. 2011 Nov 25. [View Abstract]
  28. Mosca M, Tani C, Bombardieri S. Defining undifferentiated connective tissue diseases: a challenge for rheumatologists. Lupus. 2008. 17(4):278-80. [View Abstract]
  29. Mosca M, Neri R, Bencivelli W, Tavoni A, Bombardieri S. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002 Nov. 29(11):2345-9. [View Abstract]
  30. Gupta D, Roppelt H, Bowers B, Kunz D, Natarajan M, Gruber B. Successful remission of thrombotic thrombocytopenic purpura with rituximab in a patient with undifferentiated connective tissue disorder. J Clin Rheumatol. 2008 Apr. 14(2):94-6. [View Abstract]
  31. Martorell EA, Hong C, Rust DW, Salomon RN, Krishnamani R, Patel AR. A 32-year-old woman with arthralgias and severe hypotension. Arthritis Rheum. 2008 Nov 15. 59(11):1670-5. [View Abstract]
  32. Kelly BT, Moua T. Overlap of interstitial pneumonia with autoimmune features with undifferentiated connective tissue disease and contribution of UIP to mortality. Respirology. 2018 Jan 10. 176(7):691-7. [View Abstract]
  33. Deng XL, Liu XY. Comparative Study of 181 Cases of Diffuse Connective Tissue Disease Complicated by Cardiovascular Disease. International Journal of Rheumatic Diseases. Nov 2008. 11 (Suppl. 1):A462.
  34. Oh CW, Lee SH, Heo EP. A case suggesting lymphocytic vasculitis as a presenting sign of early undifferentiated connective tissue disease. Am J Dermatopathol. 2003 Oct. 25(5):423-7. [View Abstract]
  35. Oishi Y, Arai M, Kiraku J, Doi H, Uchiyama T, Hasegawa A. Unclassified connective tissue disease presenting as cardiac tamponade: a case report. Jpn Circ J. 2000 Aug. 64(8):619-22. [View Abstract]
  36. Zhang Y, Zhang FK, Wu XN, Wang TL, Jia JD, Wang BE. Undifferentiated connective tissue diseases-related hepatic injury. World J Gastroenterol. 2008 May 7. 14(17):2780-2. [View Abstract]
  37. Williams HJ, Alarcon GS, Joks R, et al. Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD. J Rheumatol. 1999 Apr. 26(4):816-25. [View Abstract]
  38. Alarcón GS, Williams GV, Singer JZ, Steen VD, Clegg DO, Paulus HE. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connective tissue disease. J Rheumatol. 1991 Sep. 18(9):1332-9. [View Abstract]
  39. Danieli MG, Fraticelli P, Salvi A, Gabrielli A, Danieli G. Undifferentiated connective tissue disease: natural history and evolution into definite CTD assessed in 84 patients initially diagnosed as early UCTD. Clin Rheumatol. 1998. 17(3):195-201. [View Abstract]
  40. Calvo-Alen J, Alarcon GS, Burgard SL, et al. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tissue disease: multivariate analyses and identification of risk factors. J Rheumatol. 1996 Mar. 23(3):469-75. [View Abstract]
  41. Heinlen LD, McClain MT, Merrill J, Akbarali YW, Edgerton CC, Harley JB. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007 Jul. 56(7):2344-51. [View Abstract]
  42. Mosca M, Baldini C, Bombardieri S. Undifferentiated connective tissue diseases in 2004. Clin Exp Rheumatol. 2004 Jan-Feb. 17(5):22(3 Suppl 33). [View Abstract]
  43. Meroni PL, Schur PH. ANA screening: an old test with new recommendations. Ann Rheum Dis. 2010 Aug. 69(8):1420-2. [View Abstract]
  44. Tozzoli R, Bizzaro N, Tonutti E, Villalta D, Bassetti D, Manoni F, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol. 2002 Feb. 117(2):316-24. [View Abstract]
  45. Ceribelli A, Cavazzana I, Franceschini F, Quinzanini M, Rizzini FL, Cattaneo R. Isotype switching and titer variation of anti-Ro/SSA antibodies over time in 100 patients with undifferentiated connective tissue disease (UCTD). Clin Exp Rheumatol. 2008 Jan-Feb. 26(1):117-20. [View Abstract]
  46. Zold E, Szodoray P, Gaal J, Kappelmayer J, Csathy L, Gyimesi E. Vitamin D deficiency in undifferentiated connective tissue disease. Arthritis Res Ther. 2008. 10(5):R123. [View Abstract]
  47. Cortes S, Clemente-Coelho P. [Nailfold capillaroscopy in the evaluation of Raynaud's phenomenon and undifferentiated connective tissue disease]. Acta Reumatol Port. 2008 Apr-Jun. 33(2):203-9. [View Abstract]
  48. Spinillo A, Beneventi F, Epis OM, Montanari L, Mammoliti D, Ramoni V. The effect of newly diagnosed undifferentiated connective tissue disease on pregnancy outcome. Am J Obstet Gynecol. 2008 Dec. 199(6):632.e1-6. [View Abstract]
  49. Cordiali-Fei P, Mussi A, D'Agosto G, Trento E, Bordignon V, Trincone S, et al. Assessment of T regulatory cells and expanded profiling of autoantibodies may offer novel biomarkers for the clinical management of systemic sclerosis and undifferentiated connective tissue disease. Clin Dev Immunol. 2013. 2013:390563. [View Abstract]
  50. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013 Nov. 65(11):2737-47. [View Abstract]
  51. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al. American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012 Apr. 64(4):475-87. [View Abstract]
  52. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010 Sep. 62(9):2569-81. [View Abstract]
  53. Luciano N, Baldini C, Tarantini G, Ferro F, Sernissi F, Varanini V, et al. Ultrasonography of major salivary glands: a highly specific tool for distinguishing primary Sjögren's syndrome from undifferentiated connective tissue diseases. Rheumatology (Oxford). 2015 Dec. 54 (12):2198-204. [View Abstract]
  54. García-González M, Rodríguez-Lozano B, Bustabad S, Ferraz-Amaro I. Undifferentiated connective tissue disease: predictors of evolution into definite disease. Clin Exp Rheumatol. 2017 Sep-Oct. 35 (5):739-745. [View Abstract]
Inclusion Criteria Clinical



Exclusion Criteria (Applicable to patients at disease onset)



Laboratory Exclusion Criteria (Applicable to patients at disease onset)
1. Signs and symptoms suggestive of a CTD but not fulfilling the diagnostic or classification criteria for any of the defined CTDs (using previously established classification criteria for SLE, MCTD, SSc, PM/DM, RA and SS) for at least 3 years. If the disease duration is less than 3 years, patients may be defined as having an early UCTD.



Adapted from Mosca et al[10] and Doria et al.[19]



2. Presence of antinuclear antibodies determined on two different occasions



Malar rash



Subacute cutaneous lupus



Discoid lupus



Cutaneous sclerosis



Heliotrope rash



Gottron papules



Erosive arthritis



Anti-dsDNA



Anti-Smith



Anti-U1-RNP



Anti-Scl70



Anticentromere



Anti-La/SSB



Anti-Jo1



Anti-Mi2



Connective-Tissue Disease Association Signs or Symptoms Laboratory Data
Systemic lupus erythematosusAge, fever, photosensitivity, serositis, alopeciaANA, Anti-dsDNA, Anti-Smith, Anti-cardiolipin antibodies, Coombs positivity, leukopenia
Systemic sclerosisSclerodactyly, Raynaud phenomenon, sicca symptoms, esophageal dysfunctionANA with nucleolar pattern
Sjögren syndromeXerostomia, xerophthalmia, Raynaud phenomenonAnti-SSA, Anti-SSB
Rheumatoid arthritisSymmetric polyarthritisRF, elevated ESR (>70 mm/h)
Mixed connective-tissue diseaseEsophageal reflux, polyarthritis, Raynaud phenomenonANA, Anti-U1-RNP